Patent · US Active

Flavonoid treatment of glycogen synthase kinase-based disease

US8802638B1 · kind B1 · utility

1Cited by

0References

6Claims

0Family size

Assignee

University of South Florida · US

Inventors

Jun Tan · Tampa, US
Doug Shytle · Lutz, US
Kavon Rezai-Zadeh · Tampa, US

Key dates

Filing date	Apr 9, 2009
Grant date	Aug 12, 2014
Priority date	—
Expiry date	Apr 9, 2029

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K31/7048
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The flavonoid luteolin reduces amyloid-β peptide (Aβ) generation. Luteolin is also a selective GSK-3 inhibitor that 1) decreases amyloidogenic γ-secretase APP processing, and 2) promotes presenilin 1 (PS1) carboxyl-terminal fragment (CTF) phosphorylation. GSK-3α activity is essential for both PS1 CTF phosphorylation states and PS1-APP interaction. These findings were validated in vivo, using a Tg2576 Alzheimer's Disease model system. Luteolin treatment decreased soluble Aβ levels, reduced GSK-3 activity, and disrupted PS1-APP association. In addition, Tg2576 mice treated with diosmin, a glycoside of a flavone structurally and functionally similar to luteolin (diosmetin), displayed significantly reduced Aβ pathology as well.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.